Explore how TP53 mutation volume (VAF) is revolutionizing prognosis and treatment for acute myeloid leukemia patients through precision medicine approaches.
Discover how targeting BTN2A1 with a unique activating monoclonal antibody enhances Vγ9Vδ2 T cell cytotoxicity against primary acute lymphoblastic leukemia blasts.
Groundbreaking combination therapy offers fresh hope for newly diagnosed chronic lymphocytic leukemia patients with impressive clinical outcomes and quality of life improvements.
Discover how blinatumomab therapy combined with Next-Generation Sequencing is revolutionizing the treatment of adult B-cell Acute Lymphoblastic Leukemia by targeting minimal residual disease.
Explore the first comprehensive database dedicated to RNA editing in blood cell development and malignancies, providing unprecedented insights into blood production and cancers.
Discover how scientists identified the 66-68 kDa methotrexate-binding protein HSC70 in leukemia cells and its role in chemotherapy resistance.
Discover how KBH-A42, a novel HDAC inhibitor, selectively targets leukemia cells through epigenetic reprogramming and gene expression changes.